Annual Revenue
$832.00 K
-$9.43 M-91.89%
31 December 2023
Summary:
Inovio Pharmaceuticals annual revenue is currently $832.00 thousand, with the most recent change of -$9.43 million (-91.89%) on 31 December 2023. During the last 3 years, it has fallen by -$6.58 million (-88.77%). INO annual revenue is now -98.03% below its all-time high of $42.22 million, reached on 31 December 2017.INO Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
N/A
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly revenue is not available.INO Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
N/A
30 September 2024
Summary:
Inovio Pharmaceuticals TTM revenue is not available.INO TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Revenue Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -91.9% | - | - |
3 y3 years | -88.8% | - | - |
5 y5 years | -97.3% | - | - |
INO Revenue High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | -91.9% | at low | ||||
5 y | 5 years | -97.3% | at low | ||||
alltime | all time | -98.0% | +933.5% |
Inovio Pharmaceuticals Revenue History
Date | Annual | Quarterly | TTM |
---|---|---|---|
June 2024 | - | $100.80 K(-1.9%) | $591.90 K(-28.9%) |
Dec 2023 | $832.00 K(-91.9%) | $102.70 K(-73.6%) | $832.00 K(-2.6%) |
Sept 2023 | - | $388.40 K(+71.9%) | $854.00 K(-91.1%) |
June 2023 | - | $226.00 K(+96.7%) | $9.62 M(-5.5%) |
Mar 2023 | - | $114.90 K(-7.9%) | $10.18 M(-0.8%) |
Dec 2022 | $10.26 M(+478.2%) | $124.70 K(-98.6%) | $10.26 M(-6.5%) |
Sept 2022 | - | $9.15 M(+1067.0%) | $10.98 M(+419.2%) |
June 2022 | - | $784.40 K(+294.0%) | $2.11 M(+31.9%) |
Mar 2022 | - | $199.10 K(-76.3%) | $1.60 M(-9.7%) |
Dec 2021 | $1.77 M(-76.1%) | $839.10 K(+187.7%) | $1.77 M(-72.8%) |
Sept 2021 | - | $291.70 K(+6.9%) | $6.52 M(+0.9%) |
June 2021 | - | $272.80 K(-26.5%) | $6.46 M(+0.1%) |
Mar 2021 | - | $371.10 K(-93.4%) | $6.46 M(-12.9%) |
Dec 2020 | $7.41 M(+80.2%) | $5.58 M(+2262.7%) | $7.41 M(+251.2%) |
Sept 2020 | - | $236.20 K(-11.6%) | $2.11 M(-23.0%) |
June 2020 | - | $267.20 K(-79.9%) | $2.74 M(+5.0%) |
Mar 2020 | - | $1.33 M(+374.9%) | $2.61 M(-36.5%) |
Dec 2019 | $4.11 M(-86.5%) | $279.50 K(-67.8%) | $4.11 M(-35.1%) |
Sept 2019 | - | $866.90 K(+538.8%) | $6.34 M(-15.2%) |
June 2019 | - | $135.70 K(-95.2%) | $7.47 M(-76.5%) |
Mar 2019 | - | $2.83 M(+13.1%) | $31.78 M(+4.3%) |
Dec 2018 | $30.48 M(-27.8%) | $2.50 M(+25.1%) | $30.48 M(-17.1%) |
Sept 2018 | - | $2.00 M(-91.8%) | $36.77 M(-1.7%) |
June 2018 | - | $24.45 M(+1498.4%) | $37.41 M(+12.1%) |
Mar 2018 | - | $1.53 M(-82.6%) | $33.37 M(-21.0%) |
Dec 2017 | $42.22 M(+19.4%) | $8.79 M(+232.3%) | $42.22 M(+0.7%) |
Sept 2017 | - | $2.64 M(-87.0%) | $41.95 M(-19.1%) |
June 2017 | - | $20.41 M(+96.7%) | $51.84 M(+37.8%) |
Mar 2017 | - | $10.38 M(+21.9%) | $37.63 M(+6.4%) |
Dec 2016 | $35.37 M(-12.8%) | $8.51 M(-32.1%) | $35.37 M(+7.9%) |
Sept 2016 | - | $12.54 M(+102.1%) | $32.79 M(-26.2%) |
June 2016 | - | $6.20 M(-23.5%) | $44.43 M(+2.1%) |
Mar 2016 | - | $8.11 M(+36.6%) | $43.52 M(+7.3%) |
Dec 2015 | $40.57 M(+288.0%) | $5.94 M(-75.5%) | $40.57 M(+9.4%) |
Sept 2015 | - | $24.18 M(+357.4%) | $37.09 M(+151.5%) |
June 2015 | - | $5.29 M(+2.3%) | $14.75 M(+11.2%) |
Mar 2015 | - | $5.17 M(+110.3%) | $13.27 M(+26.9%) |
Dec 2014 | $10.46 M(-22.4%) | $2.46 M(+33.5%) | $10.46 M(+7.4%) |
Sept 2014 | - | $1.84 M(-51.6%) | $9.74 M(-44.0%) |
June 2014 | - | $3.80 M(+61.3%) | $17.39 M(+21.0%) |
Mar 2014 | - | $2.36 M(+35.5%) | $14.37 M(+6.7%) |
Dec 2013 | $13.47 M(+227.0%) | $1.74 M(-81.7%) | $13.47 M(+4.7%) |
Sept 2013 | - | $9.49 M(+1107.6%) | $12.86 M(+204.1%) |
June 2013 | - | $785.60 K(-46.0%) | $4.23 M(+9.0%) |
Mar 2013 | - | $1.46 M(+28.2%) | $3.88 M(-5.8%) |
Dec 2012 | $4.12 M(-58.0%) | $1.13 M(+32.8%) | $4.12 M(-10.8%) |
Sept 2012 | - | $854.70 K(+96.0%) | $4.62 M(-27.9%) |
June 2012 | - | $436.10 K(-74.2%) | $6.40 M(-23.7%) |
Mar 2012 | - | $1.69 M(+3.7%) | $8.38 M(-14.4%) |
Dec 2011 | $9.80 M | $1.63 M(-38.1%) | $9.80 M(-6.9%) |
Sept 2011 | - | $2.64 M(+9.0%) | $10.52 M(+14.9%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
June 2011 | - | $2.42 M(-22.1%) | $9.16 M(+16.3%) |
Mar 2011 | - | $3.11 M(+31.6%) | $7.88 M(+28.2%) |
Dec 2010 | $6.14 M(-32.6%) | $2.36 M(+84.9%) | $6.14 M(-4.0%) |
Sept 2010 | - | $1.28 M(+12.5%) | $6.40 M(-27.0%) |
June 2010 | - | $1.13 M(-17.4%) | $8.77 M(-13.4%) |
Mar 2010 | - | $1.37 M(-47.4%) | $10.12 M(+11.0%) |
Dec 2009 | $9.12 M(+334.8%) | $2.61 M(-28.4%) | $9.12 M(+33.4%) |
Sept 2009 | - | $3.65 M(+46.4%) | $6.83 M(+87.6%) |
June 2009 | - | $2.49 M(+574.3%) | $3.64 M(+100.8%) |
Mar 2009 | - | $369.50 K(+13.1%) | $1.81 M(-13.5%) |
Dec 2008 | $2.10 M(-56.4%) | $326.80 K(-28.1%) | $2.10 M(-58.8%) |
Sept 2008 | - | $454.70 K(-31.4%) | $5.09 M(-0.6%) |
June 2008 | - | $663.00 K(+1.5%) | $5.12 M(+3.4%) |
Mar 2008 | - | $653.00 K(-80.3%) | $4.96 M(+3.1%) |
Dec 2007 | $4.81 M(+38.6%) | $3.32 M(+582.8%) | $4.81 M(+59.3%) |
Sept 2007 | - | $486.50 K(-1.8%) | $3.02 M(-2.9%) |
June 2007 | - | $495.60 K(-1.6%) | $3.11 M(-5.1%) |
Mar 2007 | - | $503.90 K(-67.1%) | $3.27 M(-5.6%) |
Dec 2006 | $3.47 M(-36.6%) | $1.53 M(+166.0%) | $3.47 M(+25.4%) |
Sept 2006 | - | $575.80 K(-13.1%) | $2.77 M(-5.1%) |
June 2006 | - | $662.70 K(-5.1%) | $2.91 M(-44.0%) |
Mar 2006 | - | $698.00 K(-15.8%) | $5.20 M(-4.8%) |
Dec 2005 | $5.47 M(+368.5%) | $829.20 K(+14.5%) | $5.47 M(+5.5%) |
Sept 2005 | - | $724.50 K(-75.5%) | $5.18 M(+5.5%) |
June 2005 | - | $2.95 M(+206.9%) | $4.91 M(+138.5%) |
Mar 2005 | - | $961.90 K(+77.2%) | $2.06 M(+76.5%) |
Dec 2004 | $1.17 M(+1349.8%) | $542.70 K(+19.2%) | $1.17 M(+76.2%) |
Sept 2004 | - | $455.20 K(+356.1%) | $662.50 K(+188.5%) |
June 2004 | - | $99.80 K(+43.8%) | $229.60 K(+65.4%) |
Mar 2004 | - | $69.40 K(+82.2%) | $138.80 K(+72.4%) |
Dec 2003 | $80.50 K(-57.5%) | $38.10 K(+70.9%) | $80.50 K(-32.1%) |
Sept 2003 | - | $22.30 K(+147.8%) | $118.60 K(-27.8%) |
June 2003 | - | $9000.00(-18.9%) | $164.20 K(-16.3%) |
Mar 2003 | - | $11.10 K(-85.4%) | $196.20 K(+3.5%) |
Dec 2002 | $189.50 K(+71.3%) | $76.20 K(+12.2%) | $189.60 K(+67.2%) |
Sept 2002 | - | $67.90 K(+65.6%) | $113.40 K(-91.6%) |
June 2002 | - | $41.00 K(+811.1%) | $1.35 M(-37.2%) |
Mar 2002 | - | $4500.00(-99.7%) | $2.14 M(-44.1%) |
Dec 2001 | $110.60 K(-97.4%) | - | - |
Sept 2001 | - | $1.30 M(+55.4%) | $3.84 M(-6.9%) |
June 2001 | - | $837.70 K(+65.4%) | $4.12 M(-10.3%) |
Mar 2001 | - | $506.40 K(-57.5%) | $4.60 M(-17.4%) |
Mar 2001 | $4.29 M(-15.5%) | - | - |
Dec 2000 | - | $1.19 M(-25.0%) | $5.57 M(-0.2%) |
Sept 2000 | - | $1.59 M(+21.0%) | $5.58 M(+1.6%) |
June 2000 | - | $1.31 M(-11.3%) | $5.49 M(+8.1%) |
Mar 2000 | $5.08 M(-39.0%) | $1.48 M(+23.1%) | $5.08 M(-44.3%) |
Dec 1999 | - | $1.20 M(-20.0%) | $9.12 M(+3.4%) |
Sept 1999 | - | $1.50 M(+66.7%) | $8.82 M(+20.5%) |
June 1999 | - | $900.00 K(-83.7%) | $7.32 M(+14.0%) |
Mar 1999 | $8.32 M | $5.52 M(+513.5%) | $6.42 M(+613.5%) |
Dec 1998 | - | $900.00 K | $900.00 K |
FAQ
- What is Inovio Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual revenue year-on-year change?
- What is the all time high quarterly revenue for Inovio Pharmaceuticals?
- What is the all time high TTM revenue for Inovio Pharmaceuticals?
What is Inovio Pharmaceuticals annual revenue?
The current annual revenue of INO is $832.00 K
What is the all time high annual revenue for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual revenue is $42.22 M
What is Inovio Pharmaceuticals annual revenue year-on-year change?
Over the past year, INO annual revenue has changed by -$9.43 M (-91.89%)
What is the all time high quarterly revenue for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly revenue is $24.45 M
What is the all time high TTM revenue for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM revenue is $51.84 M